文献速递核素与放射性配体治疗肿瘤 PET/CT

基线68Ga-DOTATATE PET/CT定量参数预测177Lu-DOTATATE治疗反应

Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE.
PubMed 文献 · J Nucl Med · 2021-02-12

本研究纳入91例高分化神经内分泌肿瘤患者(平均Ki-67指数8.3%),在肽受体放射性核素治疗前行68Ga-DOTATATE PET/CT,其中36例在第二周期前行 interim PET,评估定量PET参数对治疗反应和无进展生存期(PFS)的预测价值。结果显示,基线肿瘤SUVmax、肝脏或脾脏为阈值的SUV比值、DTTV SUVmean及峰度等参数与治疗反应或PFS相关,而首个周期治疗后的参数变化与临床结局无关。

要点

  • 基线68Ga-DOTATATE PET/CT的SUVmax及肝脏/脾脏比值可预测治疗反应和PFS。
  • DTTV以肝脏为阈值获得的SUVmean和较低峰度与良好反应及更长PFS相关。
  • 首个周期肽受体放射性核素治疗后的PET参数变化与临床结局无关。

核心结论

  • 生长抑素受体表达程度和肿瘤异质性相关定量参数可预测治疗反应或PFS。
  • 首个周期肽受体放射性核素治疗后的参数变化与临床结局不相关。

研究设计与样本

  • 前瞻性多中心研究,纳入91例高分化神经内分泌肿瘤患者(平均Ki-67指数8.3%),平均随访12.2个月。
  • 91例中36例在第二周期治疗前接受了interim PET/CT。
  • 评估指标包括标记病灶SUVmax及其与肝脏或脾脏SUVmax的比值、分割的68Ga-DOTATATE肿瘤体积(DTTV)、以肝脏和脾脏为阈值获得的SUVmax和SUVmean,以及异质性参数(变异系数、峰度、偏度)。
  • 采用Wilcoxon秩和检验分析连续变量与治疗反应的关系,采用单变量和多变量Cox比例风险模型分析与PFS的关系。

主要发现

  • 71例为治疗反应者,20例为无反应者。
  • 标记病灶分析中,较高的平均SUVmax和平均病灶SUVmax与肝脏SUVmax比值可预测治疗反应(P=0.018和P=0.024)。
  • DTTV参数中,以肝脏为阈值获得的较高SUVmax和SUVmean以及较低峰度可预测良好反应(P=0.025、P=0.0055和P=0.031),较低峰度亦与更长PFS相关。
  • interim PET的DTTV以肝脏为阈值获得的SUVmean及interim PET靶病灶平均SUVmax与基线PET的比值与治疗反应相关(P=0.024和P=0.048),但与PFS无关。
  • 多变量分析校正年龄、原发部位和Ki-67指数后,平均SUVmax(P=0.019)、平均病灶SUVmax与肝脏SUVmax比值(P=0.018)、平均病灶SUVmax与脾脏SUVmax比值(P=0.041)、DTTV以肝脏为阈值获得的SUVmean(P=0.0052)和偏度(P=0.048)仍为PFS的显著预测因素。

临床怎么用

  • 基线68Ga-DOTATATE PET/CT定量参数有助于筛选可能从177Lu-DOTATATE治疗中获益的神经内分泌肿瘤患者。
  • 首个周期治疗后的interim PET参数变化不宜单独用于预测临床结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this study was to determine whether quantitative PET parameters on baseline 68Ga-DOTATATE PET/CT and interim PET (iPET) performed before the second cycle of therapy are predictive of the therapy response and progression-free survival (PFS). Methods: Ninety-one patients with well-differentiated neuroendocrine tumors (mean Ki-67 index, 8.3%) underwent 68Ga-DOTATATE PET/CT to determine suitability for peptide receptor radionuclide therapy as part of a prospective multicenter study. The mean follow-up was 12.2 mo. Of the 91 patients, 36 had iPET. The tumor metrics evaluated were marker lesion-based measures (mean SUVmax and ratio of the mean lesion SUVmax to the SUVmax in the liver or the SUVmax in the spleen), segmented 68Ga-DOTATATE tumor volumes (DTTVs), SUVmax and SUVmean obtained with the liver and spleen as thresholds, and heterogeneity parameters (coefficient of variation, kurtosis, and skewness). The Wilcoxon rank sum test was used for the association between continuous variables and the therapy response, as determined by the clinical response. Univariable and multivariable Cox proportional hazards models were used for the association with PFS. Results: There were 71 responders and 20 nonresponders. When marker lesions were used, higher mean SUVmax and ratio of the mean lesion SUVmax to the SUVmax in the liver were predictors of the therapy response (P = 0.018 and 0.024, respectively). For DTTV parameters, higher SUVmax and SUVmean obtained with the liver as a threshold and lower kurtosis were predictors of a favorable response (P = 0.025, 0.0055, and 0.031, respectively). The latter also correlated with a longer PFS. The iPET DTTV SUVmean obtained with the liver as a threshold and the ratio of mean SUVmax obtained from target lesions at iPET to baseline PET correlated with the therapy response (P = 0.024 and 0.048, respectively) but not PFS. From the multivariable analysis with adjustment for age, primary site, and Ki-67 index, the mean SUVmax (P = 0.019), ratio of the mean lesion SUVmax to the SUVmax in the liver (P = 0.018), ratio of the mean lesion SUVmax to the SUVmax in the spleen (P = 0.041), DTTV SUVmean obtained with the liver (P = 0.0052), and skewness (P = 0.048) remained significant predictors of PFS. Conclusion: The degree of somatostatin receptor expression and tumor heterogeneity, as represented by several metrics in our analysis, were predictive of the therapy response or PFS. Changes in these parameters after the first cycle of peptide receptor radionuclide therapy did not correlate with clinical outcomes.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ortega C, Wong RKS, Schaefferkoetter J, et al. Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE. J Nucl Med. 2021. PMID: 33579805. doi:10.2967/jnumed.120.256727

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。